Naloxona B. Braun (Naloxone Hydrochloride)

Naloxone binds competitively to µ‑opioid receptors without activating them, displacing opioid molecules and blocking their effects. This rapid receptor blockade stops opioid‑induced sedation and respiratory depression, allowing normal neuronal activity to resume.

The specific dose of Naloxona B. Braun is determined by the prescriber based on the patient’s clinical condition, the type of opioid involved, and the route of administration. Healthcare professionals follow established guidelines to select the appropriate amount.

Safety data for naloxone in pregnancy and lactation are limited. It is generally used only when the benefit to the mother outweighs potential risks to the fetus or infant. Clinicians should evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Naloxona B. Braun provides the same active ingredient, naloxone hydrochloride, as other branded or generic formulations. Differences may lie in packaging, storage requirements, and regulatory status, but the pharmacological effect—rapid opioid reversal—remains consistent across products.

Naloxona B. Braun should be stored at 2‑8 °C, refrigerated in its original container, protected from light, and never frozen or shaken. Maintaining the cold chain preserves drug potency and ensures safe administration.

The product is supplied for intramuscular or intravenous injection. Healthcare providers select the appropriate route based on the clinical scenario, inject the solution into a suitable muscle or vein, and monitor the patient for response and possible withdrawal symptoms.

Serious risks include severe hypertension, pulmonary edema, seizures, allergic reactions such as anaphylaxis, and cardiac arrhythmias. Immediate medical supervision is required to detect and manage these rare but potentially life‑threatening events.

Patients with known hypersensitivity to naloxone or any component of the formulation should not receive Naloxona B. Braun. Caution is also advised for individuals with severe cardiovascular disease, as abrupt reversal may cause hemodynamic instability.